Characterization of in-vivo human metabolites of the oral nucleoside anti-COVID-19 drug VV116 using UHPLC-Orbitrap-MS-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Characterization of in-vivo human metabolites of the oral nucleoside anti-COVID-19 drug VV116 using UHPLC-Orbitrap-MS

Published:2023-05 Issue: Volume:228 Page:115340
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Zhou Ainan,Wang Zhen,Diao Xingxing,Zhong Dafang

Funder

National Key Research and Development Program of China Stem Cell and Translational Research

Science and Technology Commission of Shanghai Municipality

National Key Research and Development Program of China

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference15 articles.

1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China;Huang;Lancet,2020

2. A pneumonia outbreak associated with a new coronavirus of probable bat origin;Zhou;Nature,2020

3. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2;Sanche;Emerg. Infect. Dis.,2020

4. FDA approval of remdesivir — a step in the right direction;Rubin;N. Engl. J. Med.,2020

5. Remdesivir: first approval;Lamb;Drugs,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A validated LC-MS/MS method for determination of six Anti-SARS-CoV-2 drugs in plasma and its application for a pharmacokinetic study in rats;Journal of Chromatography B;2024-03

2. Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study;The Lancet Infectious Diseases;2024-02

3. Therapeutic efficacy of VV116 for follicular lymphoma complicated with COVID-19: A case report;2023-11-01

4. The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review;Medicine;2023-07-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3